Showing 2011-2020 of 3223 results for "".
- Alcon Launches Precision1 for Astigmatism Contact Lenses in the UShttps://modernod.com/news/alcon-launches-precision1-for-astigmatism-contact-lenses-in-the-us/2478780/Alcon announced the US launch of Precision1 for Astigmatism, a daily disposable, silicone hydrogel (SiHy) contact lens designed for astigmatic patients. “Precision1, with its cutting-edge Smartsurface technology, has become the fastest-growing daily disposable contact lens brand in the U.S
- Oxurion NV Appoints Prof Alan Stitt as Chief Scientific Officerhttps://modernod.com/news/oxurion-nv-appoints-prof-alan-stitt-as-chief-scientific-officer/2478775/Oxurion has announced the appointment of Professor Alan Stitt, PhD, as the company’s Chief Scientific Officer (CSO), effective January 19, 2021. This appointment follows the retirement of current CSO Jean Feyen, PhD, who has served in this position since joining the company in 2013. Dr. Feyen wil
- CDC Expands Negative COVID-19 Test Requirement to All Air Passengers Entering the United Stateshttps://modernod.com/news/cdc-expands-negative-covid-19-test-requirement-to-all-air-passengers-entering-the-united-states/2478761/The Centers for Disease Control and Prevention is expanding the requirement for a negative COVID-19 test to all air passengers entering the United States. Testing before and after travel is a critical layer to slow the in
- Early Study Shows J&J’s One-Dose COVID-19 Vaccine Triggered Antibodies in all Participantshttps://modernod.com/news/early-study-shows-jjs-one-dose-covid-19-vaccine-triggered-antibodies-in-all-participants/2478759/Detailed phase 1/2a study findings published in the NEJM on Wednesday showed that all volunteers given Johnson & Johnson’s single-dose coronavirus vaccine Ad26.COV2.S had detectable neutralizing antibodies by day 57. In September, the company reported a preview of the interim results in
- Biden Aims to Release All Available COVID-19 Vaccine Doses to Speed Up Distribution: Reporthttps://modernod.com/news/biden-aims-to-release-all-available-covid-19-vaccine-doses-to-speed-up-distribution-report/2478739/President-elect Joe Biden will seek to release nearly every available dose of the coronavirus vaccine when he takes office later this month, a move that signals a departure from the Trump administration and the FDA’s current stance of holding back half of the US vaccine supply in order to e
- Alcon Commercially Launches AcrySof IQ Vivity Extended Depth of Focus IOL in UShttps://modernod.com/news/alcon-launches-acrysof-iq-vivity-extended-depth-of-focus-iol-in-us/2478731/Alcon has commercially launched the AcrySof IQ Vivity IOL, which the company describes as the first and only non-diffractive extended depth of focus IOL in the United States. Vivity is a first-of-its-kind, non-diffractive extended depth of focus IOL with Alcon’s proprietary non-diffractiv
- Ocular Therapeutix Submits Supplemental NDA for Dextenza for Treatment of Ocular Itching Associated with Allergic Conjunctivitishttps://modernod.com/news/ocular-therapeutix-submits-supplemental-nda-for-dextenza-for-treatment-of-ocular-itching-associated-with-allergic-conjunctivitis/2478693/Ocular Therapeutix announced the submission of the supplemental new drug application (sNDA) to the FDA for Dextenza (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use. If approved, this sNDA would include the treatment of ocular itching associated with allergic conjunctivitis as an
- Regenxbio Announces Dosing of First Patient in Phase 2 ALTITUDE Trial of RGX-314 for the Treatment of DRhttps://modernod.com/news/regenxbio-announces-dosing-of-first-patient-in-phase-2-altitude-trial-of-rgx-314-for-the-treatment-of-dr/2478651/Regenxbio announced that the first patient has been dosed in ALTITUDE, a phase 2 trial to evaluate the suprachoroidal delivery of RGX-314 using the SCS Microinjector for the treatment of diabetic retinopathy (DR). “We are pleased to announce the first patient dosed in our ALTITUDE tr
- Alsanza Announces Global Launch of Alsee Zero Glistening, Zero Haze Hydrophobic Monofocal IOLhttps://modernod.com/news/alsanza-globally-launches-zero-glistening-zero-haze-hydrophobic-monofocal-iol-alsee/2478652/Germany-based Alsanza announced the launch of the Alsee Zero Glistening Zero Haze Hydrophobic Monofocal IOL. The Alsee IOL is developed and designed to provide long-term clarity and high-contrast sensitive quality of vision with its 24-hour aspheric optic design. Alsee Zero Glistening Zero
- MHRA Advises Against Use of Pfizer, BioNTech’s COVID-19 Vaccine in Those With “Significant History” of Allergic Reactionshttps://modernod.com/news/mhra-advises-against-use-of-pfizer-biontechs-covid-19-vaccine-in-those-with-significant-history-of-allergic-reactions/2478646/The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) on Wednesday warned that people who have a “significant history” of allergic reactions should not receive Pfizer and BioNTech’s COVID-19 vaccine BNT162b2. The regulator issued the alert because two NHS wor